



International
Federation of
Pharmaceutical
Manufacturers &
Associations

Fédération
Internationale de
l'Industrie du
Médicament

Federación
Internacional de la
Industria del
Medicamento



News Release

IFPMA appoints New Director of Intellectual Property and Trade

Geneva, 8 December 2009 – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing the global research-based pharmaceutical industry, announces the appointment of Mr. Andrew P. Jenner as its new Director of Intellectual Property and Trade, with effect from today.

“Intellectual property is essential for continued innovation in medicines and plays a fundamental role in our industry’s business model,” said Michael D. Boyd, Acting Director General of the IFPMA. “Our new IP Director, Andrew Jenner, is a respected figure in IP circles and has extensive experience in this important area. He takes over responsibility for IP and trade matters at the IFPMA from Dr. Jacques Gorlin, a consultant for the IFPMA, who has done a tremendous job covering this function on a temporary basis during this year.”

A British citizen, Mr. Jenner worked previously in the UK Government’s Intellectual Property Office (IPO), where he started as a Patent Examiner in 1998. He was promoted Head of Trade & Development in 2004 and then Head of IP Crime Policy in 2007. While at the IPO, he played a key part in the development of the EU Regulation on the compulsory licensing of pharmaceutical products for export. He has a BA in Mechanical Engineering, a MA in Law and a Post Graduate Diploma in Law, all from the University of Wales.

(ends)

About the IFPMA:

The International Federation of Pharmaceutical Manufacturers & Associations is the global non-profit NGO representing the research-based pharmaceutical, biotech and vaccine sectors. Its members comprise 25 leading international companies and 45 national and regional industry associations covering developed and developing countries. The industry's R&D pipeline contains hundreds of new medicines and vaccines being developed to address global disease threats, including cancer, heart disease, HIV/AIDS and malaria. The IFPMA Clinical Trials Portal (www.ifpma.org/ClinicalTrials), the IFPMA's Ethical Promotion online resource (www.ifpma.org/EthicalPromotion/) and its Developing World Health Partnerships information (www.ifpma.org/HealthPartnerships) help make the industry's activities more transparent. The IFPMA strengthens patient safety by improving risk assessment of medicines and combating their counterfeiting. It also provides the secretariat for the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

For further information, please contact:

Guy Willis
Director of Communications
E-mail: g.willis@ifpma.org
Tel: +41 22 338 32 00
Fax: +41 22 338 32 99
Web: www.ifpma.org